Leiden, Netherlands, May 2024 – Veronique Joubert has joined Ncardia and Cellistic as the new Chief Human Resources Officer ad interim. With extensive experience in strategic and operational HR roles, Veronique is set to enhance the HR functions at both organizations.
Veronique Joubert’s most recent role is as a Human Resources Interim Manager & Professional Coach for individuals and teams. Since April 2016, she has been working as a freelance professional, taking on various interim HR roles such as Human Resources Manager, Head of Talent, and Senior HR Consultant for large international corporations and fast-growing SMEs. Her expertise lies in managing complex HR operations, delivering high-performance results, and exceptional stakeholder management.
Prior to her freelance career, Veronique was the Head of Talent Acquisition BeLux ad interim at ISS Facility Services Belgium & Luxembourg from May 2023 to March 2024. In this role, she managed talent acquisition across six sites and provided professional coaching to teams, driving successful recruitment strategies and employee development programs.
She also served as the Talent Acquisition Manager ad interim at Puratos from October 2021 to March 2023, overseeing talent acquisition for five sites in Belgium and the headquarters. Her role included managing recruitment processes, enhancing internal mobility, and implementing HR projects focused on digital transformation, diversity, and inclusion.
Earlier in her career, Veronique held the position of Recruitment Manager & Coach BeLux ad interim at Accenture Belgium from February 2021 to August 2021. She was responsible for leading recruitment activities, coaching teams, and optimizing recruitment processes to ensure high-quality talent acquisition.
About Ncardia: Ncardia is a drug discovery company and expert in human iPSC technology. We operate worldwide with facilities, offices, and staff throughout Europe and North America. We work with biopharmaceutical companies in drug discovery worldwide, leveraging the power of stem cell technologies in the development of novel therapies of multiple modalities at any stage of development.
Over the past 10 years, we have built the expertise and infrastructure required to differentiate, manufacture, and characterize high-quality iPSC-derived cell and disease models. We facilitate the process of disease modeling and high-throughput screening to accelerate drug discovery. We listen to our customer’s project plans, questions, and challenges, and co-develop human iPSC-based solutions that fit their specifications.
About Cellistic: Launched in April 2022, Cellistic specializes in process development and manufacture of cell therapies based on human induced pluripotent stem cell (iPSC) technology. The company’s focus and expertise in iPSC generation and differentiation protocol development makes it well-positioned to partner with innovative cell therapy developers to establish novel advanced therapies. With more than a decade of scientific and technical knowledge transfer from sister company Ncardia, Cellistic is uniquely experienced in designing and optimizing manufacturing procedures for iPSCs that deliver quality products at scale.
Read Also : Imagination in a Disrupted Age: Navigating the Future with Curiosity and Empathy
